J Korean Endocr Soc.  2007 Jun;22(3):188-191. 10.3803/jkes.2007.22.3.188.

Effect of Fenofibrate and Exercise on Metabolic Syndrome and Hepatic Steatosis

• Cha BS
• Lee JH

• KMID: 1512030
• DOI: http://doi.org/10.3803/jkes.2007.22.3.188

Abstract

No abstract available.

MeSH Terms

Fenofibrate*
Fenofibrate

Reference

1. Almind K, Bjoorbaek C, Vestergaard H, Hansen T. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet. 1993. 342:828–832.

2. Vollenwieder P, Menard B, Nicod P. Insulin resistance, defective insulin receptor substrate 2-associated phosphatidylinositol-3' kinase activation, and impaired atypical protein kinase C (zeta/lambda) activation in myotubes from obese patients with impaired glucose tolerance. Diabetes. 2002. 51:1052–1059.

3. McGarry JD, Dobibins RL. Fatty acid, lipotoxicity and insulin secretion. Diabetologia. 1999. 42:128–138.

4. O'connor BJ, Kathamna B, Tavill AS. Nonalcoholic fatty liver (NASH) syndrome. Gastroenterologist. 1997. 5:316–329.

5. Diehl AM. Nonalcoholic steatohepatitis. Semin liver dis. 1999. 19:220–229.

6. Sparrow D, Borkan GA, Gerzof SG. Relationship of fat distribution to glucose tolerance. Diabetes. 1986. 35:411–415.

7. Roden Michael. Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Prac Endocrinol Metab. 2006. 6:335–348.

8. Lavoie JM, Gauthier MS. Regulation of fat metabolism in the liver: link to nonalcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci. 2006. 63:1393–1409.

9. Hevener A, Olfesky J. exercise and thiazolidinedione therapy normalize insulin action in zucker fatty rat. Diabetes. 2000. 49:2154–2159.

10. Lee KI, Kim JM, Park JY, Kim JW, Mok JY, Park MK, Lee HJ, Hong SH, Wenjun Li, Kim DK. The effect of fenofibrate and exercise on metabolic syndrome and hepatic steatosis in OLETF rats. J Kor Endocrinol Soc. 2007. 22:192–202.

11. Carlson CL, Winder WW. Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. J Appl Physiol. 1999. 86:669–674.

12. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001. 108:1167–1174.

13. Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderrman N, Saha AK. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 2002. 277:32571–32577.

14. Costet P, Legendre L, More J, Fdgar A. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998. 273:29577–29585.

15. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000. 275:16638–16642.

16. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001. 491:154–158.

17. Sato O, Kurik IC, Fukui Y, Motijima K. Dual promotor structure of mouse and human fatty acid translocse/cd36 genes and unique transcriptional activation by PPAR α and γ ligands. J Biol chem. 2002. 277:15703–15711.

18. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLEFT rats. Biochem Biophys Res Commun. 2002. 296:293–299.

19. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL. Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem. 2006. 285:35–50.

20. Chan L, Wei CF, Li WH, Yang CY, Ratner P, Pownall H, Gotto AM, Smith LC. Human liver fatty acid binding protein cDNA and amino acid sequence. Functional and evolutionary implications. J Biol Chem. 1985. 260:2629–2632.

21. Perseghin G, Lattuada G, De Cobelli F, Ragogna F, Ntali G, Esposito A, Belloni E, Canu T, Terruzzi I, Scifo P, Del Maschio A, Luzi L. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 2007. 30:683–688.

22. Gauthier MS, Couturier K, Latour JG, Lavoie JM. Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis. J Appl Physiol. 2003. 94:2127–2134.